Meet Our Leadership

Learn more about our founders and the management team at Advanced Cancer Therapeutics.

about advanced cancer therapeutics  

Advanced Cancer Therapeutics (ACT) is leading innovation within the biotechnology industry. Founded in January 2007, the company is focused on the discovery and early development of novel cancer therapeutics as well as selection for partnership, commercialization and manufacture of the most promising discoveries. Utilizing its groundbreaking business arrangement with the James Graham Brown Cancer Center and the University of Louisville Research Foundation, ACT will establish exclusive rights to specific novel therapeutics and fast-track these leading edge discoveries to the pharmaceutical industry, and ultimately the patients who need them.

recent news

ACT's compound PFK-158 featured in CEO/CFO Magazine; Announces MD Anderson and UT Health Science Center San Antonio added as clinical trial sites. Click HERE to read more.

ACT was awarded #3 in The University of Houston's Cougar 100 companies! Click HERE to read more.

ACT's compound PFK-158 has been chosen by Informa and Kantar Health as one of the "2014 Top 10 Most Interesting Oncology Projects to Watch". Click  HERE  to read more.

ACT is currently conducting a Phase I, open label, dose escalation, multicenter clinical trial in patients with advanced solid tumors. The study is to evaluate the safety, tolerability and antitumor activity of PFK158, a small molecule therapeutic candidate. The centers involved with the study are the Brown Cancer Center at the University of Louisville and the Lombardi Cancer Center at Georgetown University.

ACT presented a poster during the 2014 AACR Annual meeting, titled “Grich DNA Genomic Sequences Derived from the Promoter Region of ProOncogenes Inhibit Tumor Growth and Demonstrate Synergies”, that highlighted the preclinical properties of oligonucleotides inhibiting cMyc, Bcl2, and Kras.

Dr. Jason Chesney, Deputy Director, Brown Cancer Center, was invited to make an oral presentation at the 2014 AACR annual meeting on PFK158. The presentation, titled “Identification of a PFKFB3 inhibitor suitable for phase I trial testing that synergizes with the BRaf inhibitor vemurafenib” highlighted the preclinical characteristics of PFK158 and described its synergy with BRAF inhibitors.

Advanced Cancer Therapeutics

Learn About Our Product Pipeline

More About Our Business Strategy